Frequency Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 81.58 million compared to USD 84.69 million a year ago. Basic loss per share from continuing operations was USD 116.5 compared to USD 123.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.4 USD | +3.71% | -9.55% | -3.19% |
May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.19% | 430M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- KRRO Stock
- News Korro Bio, Inc.
- Frequency Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022